Evidence for the Management of Bronchopulmonary Dysplasia in Very Preterm Infants by Muehlbacher, Tobias et al.








Evidence for the Management of Bronchopulmonary Dysplasia in Very
Preterm Infants
Muehlbacher, Tobias ; Bassler, Dirk ; Bryant, Manuel B
Abstract: Background: Very preterm birth often results in the development of bronchopulmonary dyspla-
sia (BPD) with an inverse correlation of gestational age and birthweight. This very preterm population
is especially exposed to interventions, which affect the development of BPD. Objective: The goal of our
review is to summarize the evidence on these daily procedures and provide evidence-based recommen-
dations for the management of BPD. Methods: We conducted a systematic literature research using
MEDLINE/PubMed on antenatal corticosteroids, surfactant-replacement therapy, caffeine, ventilation
strategies, postnatal corticosteroids, inhaled nitric oxide, inhaled bronchodilators, macrolides, patent
ductus arteriosus, fluid management, vitamin A, treatment of pulmonary hypertension and stem cell
therapy. Results: Evidence provided by meta-analyses, systematic reviews, randomized controlled tri-
als (RCTs) and large observational studies are summarized as a narrative review. Discussion: There
is strong evidence for the use of antenatal corticosteroids, surfactant-replacement therapy, especially in
combination with noninvasive ventilation strategies, caffeine and lung-protective ventilation strategies.
A more differentiated approach has to be applied to corticosteroid treatment, the management of patent
ductus arteriosus (PDA), fluid-intake and vitamin A supplementation, as well as the treatment of BPD-
associated pulmonary hypertension. There is no evidence for the routine use of inhaled bronchodilators
and prophylactic inhaled nitric oxide. Stem cell therapy is promising, but should be used in RCTs only.
DOI: https://doi.org/10.3390/children8040298






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Muehlbacher, Tobias; Bassler, Dirk; Bryant, Manuel B (2021). Evidence for the Management of Bron-




Evidence for the Management of Bronchopulmonary Dysplasia
in Very Preterm Infants
Tobias Muehlbacher * , Dirk Bassler and Manuel B. Bryant


Citation: Muehlbacher, T.; Bassler,
D.; Bryant, M.B. Evidence for the
Management of Bronchopulmonary
Dysplasia in Very Preterm Infants.
Children 2021, 8, 298. https://
doi.org/10.3390/children8040298
Academic Editor: Elizabeth Asztalos
Received: 10 March 2021
Accepted: 9 April 2021
Published: 13 April 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
Department of Neonatology, University Hospital Zurich, 8091 Zurich, Switzerland; dirk.bassler@usz.ch (D.B.);
manuel.bryant@usz.ch (M.B.B.)
* Correspondence: tobias.muehlbacher@usz.ch
Abstract: Background: Very preterm birth often results in the development of bronchopulmonary
dysplasia (BPD) with an inverse correlation of gestational age and birthweight. This very preterm
population is especially exposed to interventions, which affect the development of BPD. Objective:
The goal of our review is to summarize the evidence on these daily procedures and provide evidence-
based recommendations for the management of BPD. Methods: We conducted a systematic literature
research using MEDLINE/PubMed on antenatal corticosteroids, surfactant-replacement therapy,
caffeine, ventilation strategies, postnatal corticosteroids, inhaled nitric oxide, inhaled bronchodila-
tors, macrolides, patent ductus arteriosus, fluid management, vitamin A, treatment of pulmonary
hypertension and stem cell therapy. Results: Evidence provided by meta-analyses, systematic
reviews, randomized controlled trials (RCTs) and large observational studies are summarized as
a narrative review. Discussion: There is strong evidence for the use of antenatal corticosteroids,
surfactant-replacement therapy, especially in combination with noninvasive ventilation strategies,
caffeine and lung-protective ventilation strategies. A more differentiated approach has to be applied
to corticosteroid treatment, the management of patent ductus arteriosus (PDA), fluid-intake and
vitamin A supplementation, as well as the treatment of BPD-associated pulmonary hypertension.
There is no evidence for the routine use of inhaled bronchodilators and prophylactic inhaled nitric
oxide. Stem cell therapy is promising, but should be used in RCTs only.
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1. Introduction
Bronchopulmonary dysplasia (BPD) is one of the most common morbidities in very
preterm infants. In 1967, Northway introduced the term “bronchopulmonary dysplasia”
for the fibrotic pulmonary remodeling of preterm infants after respiratory distress syn-
drome [1]. The definition of BPD changed since Northway’s definition of oxygen demand
at 28 days of life: first, to the oxygen requirement at 36 weeks postmenstrual age (PMA) [2]
and, then, to the “new” (in the cited studies most commonly used) criteria of the National
Institutes of Child Health and Human Development (NICHD)/National Heart, Lung,
and Blood Institute (NHLBI) workshop of 2001 that was developed with the purpose of
identifying affected patients in a more precise way and quantifying the severity of the
disease [3]. The latter defines BPD as oxygen demand at 28 days of life and a stratification
of severity at 36 weeks PMA by the need for supplemental oxygen and respiratory support
(Table 1). However, the definition of BPD is still a matter of ongoing debate regarding
the changes in neonatal care during the last decades, e.g., the widespread use of a nasal
cannula with different flow settings [4]. The incidence of BPD ranges from 10% to 40%,
with an inverse correlation with gestational age and birthweight [5]. As neonatal intensive
care substantially improved, the mortality rate of preterm infants decreased; however, the
rates of BPD remained basically the same or even increased as more immature infants
survived [6,7]. Addressing the change in the pathophysiological mechanism of BPD de-
velopment, Jobe coined the term “new” BPD for an altered lung development in these
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extremely preterm infants in contrast to the pre-surfactant lung injury to oxygen toxicity
and aggressive mechanical ventilation [8]. A complex mixture of developmental plasticity,
inflammation, injury and repair of the immature lungs leads to the clinical entity “BPD”
with altered alveolarization and vascularization [9]. It is associated with long-term sequelae
as persistent respiratory symptoms, impaired lung function, pulmonary hypertension and
adverse neurodevelopmental outcomes and is therefore associated with increased rates of
rehospitalization and late mortality [4,5,10,11]. As no “silver bullet” for the prevention or
treatment of BPD exists, it is essential to apply a multifactorial approach to the management
of BPD in very preterm infants. This review focuses on everyday strategies regarding the
management of BPD and on controversially discussed interventions and their impact on
developing BPD.
Table 1. Bronchopulmonary dysplasia (BPD) definition by the criteria of the National Institutes
of Child Health and Human Development (NICHD)/National Heart, Lung, and Blood Institute
(NHLBI) workshop of 2001 [3].
BPD Severity Criteria
mild
Supplemental oxygen on 28th day of life and no supplemental
oxygen at 36 weeks PMA
moderate Supplemental oxygen of >21% but <30% at 36 weeks PMA
severe
Supplemental oxygen >30% or positive airway pressure or
mechanical ventilation at 36 weeks PMA
PMA: postmenstrual age.
2. What Is the Evidence for?
2.1. Antenatal Corticosteroids
Prophylactic treatment with antenatal corticosteroids (ANS) to accelerate lung mat-
uration has been first described by Liggins and Howie in a randomized controlled trial
(RCT) in 1972 aiming at the severity of respiratory distress syndrome [12]. The effect on an
additionally decreased neonatal mortality and other morbidities in a systematic review [13]
led to the NIH consensus paper recommending antenatal corticosteroids for impending
preterm birth from 24 weeks to 34 weeks of gestation [14]. The most common regimens
consist of two doses of intramuscular injection of 12-mg betamethasone 24 h apart or four
doses of 6-mg betamethasone every 12 h [15]. A recent meta-analysis included 30 ran-
domized controlled trials with 8158 preterm infants that confirmed the previous findings
with a reduction of perinatal death (relative risk (RR) 0.72, 95% confidence interval (CI)
0.58–0.89, n = 6729), but no reduction of BPD could be shown (RR 0.86, 95% CI 0.42–1.79,
n = 818) [16]. A similar result has been shown by large prospective population-based
observational studies [17–19] and by a meta-analysis of studies involving small for gesta-
tional age infants [20]. However, the before mentioned Cochrane review did not evaluate
the effects of ANS in extremely preterm infants due to a lack of sufficient data in RCTs.
A meta-analysis of observational studies analyzing these particular infants born before
25 weeks of gestation also found a highly significant reduction in mortality (odds ratio (OR)
0.48, 95% CI 0.42–0.55, n = 13,443) [21]. The BPD rate was higher in this study (OR 1.32,
95% CI 1.04–1.67, n = 7983), but the composite outcome of BPD and death was reduced
by the use of ANS (OR 0.58, 95% CI 0.42–0.79, n = 11782) [21]. The results reflected the
competitive outcomes of mortality and bronchopulmonary dysplasia in extremely preterm
infants. Two further population-based studies not included in the meta-analysis showed
a higher BPD rate and lower mortality as well but did not report on the composite out-
come [22,23]. Others could show a reduction of both BPD and the mortality rates [24–26].
The overall efficiency of ANS depends on the optimum timing of the ANS. Exposure to
a completed course of ANS with an interval from 24 h up to seven days after the last
injection is the most effective strategy [23–25,27,28]. An incomplete course or an interval
longer than seven days was less efficient, nonetheless resulting in a better outcome than
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no exposure to ANS [23,25,27,28]. Another Cochrane review analyzed whether (weekly)
repeated courses of ANS are beneficial compared to a single course. They could show a
reduction of severe respiratory distress syndrome, yet without an effect on the long-term
morbidity or mortality [29]. A post-hoc analysis of a multicenter trial showed a higher
mortality in infants of mothers treated with three or more courses of ANS [30].
2.2. Surfactant Replacement Therapy
The introduction of surfactant replacement therapy in preterm infants with respira-
tory distress syndrome by Fujiwara et al. 1980 was a game-changing event in neonatal
medicine [31]. The regular administration of surfactant in preterm infants led to the change
from the “old” to “new” bronchopulmonary dysplasia [8]. Multiple meta-analyses on the
RCTs of the 1990s showed a reduction of the overall mortality and, especially, mortality due
to respiratory distress syndrome by surfactant replacement therapy [32–36]. However, no
effect could be shown on the incidence of BPD, as now more and, especially, more immature
babies survived. Different types of surfactant have proven effective in the treatment of res-
piratory distress syndrome and the reduction of mortality: synthetic surfactants containing
surfactant proteins [37] or protein-free formulation [35] and animal-derived surfactants [36].
A meta-analysis could show a slight superiority of animal-derived surfactants compared
to protein-free surfactants regarding mortality (RR 0.89, 95% CI 0.79–0.99, n = 5413) and,
with borderline significance, the combined outcome BPD at 28 days of life or death (RR
0.95, 95% CI 0.91–1.00, n = 3811) [38]. However, there was no difference in BPD at 36 weeks
of postmenstrual age (PMA) (RR 0.99, 95% CI 0.91–1.09, n = 1896) or combined outcome
BPD at 36 weeks PMA or death (RR 0.97, 95% CI 0.90–1.04), neither in prevention nor
treatment trials [38]. There was also no difference in mortality or BPD in a meta-analysis
evaluating animal-derived surfactants versus protein-containing synthetic surfactants [39].
Two meta-analyses on RCTs comparing bovine and porcine surfactants showed conflicting
results. Singh et al. reported an inferiority of bovine surfactant compared to poractant
with increased rates of mortality (RR 1.44, 95% CI 1.04–2.00, n = 901) and combined BPD
or mortality (RR 1.30, 95% CI 1.04–1.64) [40]. There was no difference in the rates of BPD
at 36 weeks PMA (RR 0.94, 95% CI 0.79–1.12, n = 899). In a subgroup analysis at the
initial dose of poractant (≤ 100 mg/kg versus > 100 mg/kg), these results remained only
in the group with the (recommended) higher initial dose of poractant [40]. In contrast,
Sánchez-Luna et al. included more recent RCTs and found no difference in mortality (OR
1.35, 95% CI 0.98–1.86) or BPD at 36 weeks PMA (OR 1.25, 95% CI 0.96–1.62), but no data on
the combined outcome BPD or death has been given in this meta-analysis [41]. They also
addressed the question about the recommended dosage regimen: Trials with 100 mg/kg for
beractant and poractant showed no differences in BPD or mortality [41–47]. Trials using the
recommended dosage of 100 mg/kg beractant versus 200 mg/kg poractant for the initial
dose, followed by 100 mg/kg for subsequent doses, showed no difference in mortality (OR
1.39, 95% CI 0.81–2.38) but a borderline significance of BPD at 36 weeks PMA in favor of
poractant (OR 1.34, 95% CI 1.00–1.79) [41].
Not alone, surfactant replacement therapy but, especially, the way of administration
and respiratory management around surfactant application have an impact on the devel-
opment of BPD. The routine application of continuous positive airway pressure (CPAP)
and more restrictive use of mechanical ventilation, as described in the section Ventilation
Strategies, led to different surfactant administrations. A meta-analysis on INtubation—
Surfactant–Extubation (INSURE) versus nasal CPAP without surfactant showed only a
trend without significance favoring INSURE regarding mortality (RR 0.94,
95% CI 0.67–1.32), BPD (RR 0.86, 95% CI, 0.71–1.03) and combined BPD or death (RR
0.88, 95% CI, 0.76–1.02) with a moderate level of evidence [48]. One recent randomized con-
trolled trial extended the INSURE procedure by a recruitment maneuver (REC) with high-
frequency oscillation ventilation before surfactant administration (IN-REC-SUR-E) [49].
Compared to INSURE, fewer infants treated with IN-REC-SUR-E needed mechanical ven-
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tilation during the first 72 h of life; however, there was no difference in the incidence of
moderate-to-severe BPD or (per-protocol) mortality [49].
In order to avoid any mechanical ventilation, surfactant administration via a small
catheter in spontaneously breathing infants has been established, mostly named as “less-
invasive surfactant administration (LISA)” or “minimally invasive surfactant therapy
(MIST)”. Consistent results were presented by three meta-analyses favoring LISA/MIST
compared to the invasive application of surfactants with a significant reduction in BPD
with an OR ranging from 0.47 to 0.72 [50–52] and combined BPD or death (OR ranging
from 0.74 to 0.75) [50,51]. A network meta-analysis of Isayama et al. found LISA to be
the best strategy for noninvasive respiratory management [53]. Compared to a surfactant
with continued mechanical ventilation, LISA has a reduced combined rate of BPD or
death (OR 0.49, 95% CI 0.30–0.79 and BPD (OR 0.53, 95% CI 0.27–0.96), with the quality of
evidence graded as moderate [53]. Another more recent network meta-analysis of Bellos
et al., including RCTs and observational studies, could show the superiority of LISA/MIST
compared to INSURE regarding both the mortality (OR 0.64, 95% CI 0.54–0.76) and BPD
(OR 0.57, 95% CI 0.44–0.73) [54]. The subgroup analysis of infants born before 28 weeks
of gestation did not report on BPD but showed the feasibility and efficacy of LISA/MIST
in this particularly vulnerable population, with a reduction in mortality (OR 0.56, 95% CI
0.46–0.67) [54].
2.3. Caffeine
Caffeine is a methylxanthine that acts as a nonspecific inhibitor of adenosine receptors.
There are four different adenosine receptors, and caffeine inhibits three of them (A1, A2A
and A2B) [55,56]. Adenosine is a purine nucleoside that is produced naturally in different
human tissues [57]. Caffeine stimulates breathing by various mechanisms. Among others,
it has an effect on the diaphragm, minute ventilation and sensitivity to carbon dioxide (CO2)
sensitivity. It is thanks to the efforts of the Caffeine for Apnea of Prematurity (CAP) Trial
Group headed by Barbara Schmidt that we have high-quality and reliable data not only on
short-term but also long-term outcomes of caffeine use in extremely preterm infants [58].
CAP was launched to determine whether survival without neurodevelopmental
disability at a corrected age of 18 months is improved if apnea of prematurity is managed
without caffeine in infants at a high risk of apneic attacks [58]. However, the trial confirmed
that caffeine has another clinically important benefit, a reduction in the risk of BPD: 350
out of 963 infants assigned caffeine (36.3%) received supplemental oxygen at 36 weeks
PMA, as compared with 447 out of 954 infants (46.9%) assigned a placebo (OR 0.63, 95% CI
0.52–0.76) [58].
The median age of starting study medication in the CAP trial was three days, and
the median age of stopping caffeine was 34.4 weeks PMA [58]. Neonatologists asked
the question of whether caffeine started earlier than three days, and given longer than
35 weeks, PMA further improves health outcomes. The European consensus guidelines on
the management of respiratory distress syndrome recommend that “early caffeine should
be considered for babies at high risk of needing mechanical ventilation such as those on
non-invasive respiratory support” [59], and this recommendation is supported by various
observational studies and systematic reviews [60,61]. Several recent meta-analyses on high
versus standard maintenance doses of caffeine came to similar conclusions that high-dose
caffeine citrate (10–20 mg/kg per day) might reduce the incidence of BPD, but no general
recommendation can be given due to the low quality of evidence [62–65]. The use of
therapeutic drug monitoring of caffeine in routine practice could improve its effects on
chronic lung disease and avoid the side effects of high doses [66,67].
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2.4. Ventilation Strategies
Mechanical ventilation in animals can induce structural and inflammatory changes
that mimic human BPD [68,69]. There is a strong link between the use of supplemental
oxygen and mechanical ventilation and the incidence of BPD [5]. There are few doubts,
that mechanical ventilation, as well as the use of oxygen, are both the risk indicator and
risk factor in the pathogenesis of BPD [9]. Therefore, the first and most important advice
for mechanical ventilation to prevent BPD is: do not do it [70]. However, a solid number of
infants are still unable to survive without mechanical ventilation, and despite a substantial
number of RCTs in ventilation strategies, there is uncertainty about how to ventilate in the
least harmful manner [71].
Cochrane reviews cover the topics of synchronization [72], elective high-frequency
oscillation (HFO) [73], high-frequency jet ventilation (HFJV) [74,75], volume-targeted
ventilation [76], positive end-expiratory pressure (PEEP) application [77], inspiratory
times [78], permissive hypercapnia [79], neurally adjusted ventilatory assist [80] and the
type of trigger that is used for synchronization [81].
2.4.1. High-Frequency Ventilation
High-frequency ventilation therapy is using much smaller tidal volumes than con-
ventional ventilation. Considering volutrauma as a major contributing factor to ventilator-
induced lung injury, minimizing tidal volumes is a promising strategy. A Cochrane
review summarized the results of 19 RCTs on elective high-frequency oscillation ventila-
tion (HFOV). The combined outcome death or BPD at 36 weeks PMA was reduced with
HFOV (RR 0.90, 95% CI 0.84–0.97, n = 3329), resulting mainly from a reduction in BPD
(RR 0.86, 95% CI 0.78–0.96, n = 2786) but with significant heterogeneity between studies.
However, using a random-effects model, the reduction of BPD and BPD or death remained
significant [73]. The meta-analysis showed an increased incidence of pulmonary air leak
(RR 1.19, 95% CI 1.05–1.34), likely due to higher mean airway pressures applied during
HFOV [73].
As a consequence of the previous version of this Cochrane review [82], which was crit-
icized because of the heterogeneity of the patient characteristics, ventilators and ventilation
strategies used, the authors conducted a patient meta-analysis including 3329 participants
from 10 RCTs for which individual patient data were available [83]. The risk of death or
BPD at 36 weeks PMA with HFOV was 0.95 (95% CI 0.88–1.03). No subgroup of infants,
ventilator type or strategy could be linked to a stronger treatment effect. However, only one
of these 10 RCTs used a volume-targeted ventilation mode in the conventional treatment
arm. Modern respirators have substantially improved regarding synchronization and tidal
volume measurements; therefore, there is a need for RCTs comparing volume-targeted
ventilation modes and HFOV [84].
Evidence of high-frequency jet ventilation (HFJV) in very preterm infants is very
scarce. A Cochrane review comparing HFOV with HFJV was empty, and a meta-analysis
for HFJV versus conventional found only one RCT conducted in the 1980s [85]; therefore,
the routine application of HFJV cannot be recommended.
2.4.2. Volume-Targeted Ventilation
Ventilator-induced injury happens mainly in the high-volume injury zone (overinfla-
tion, volutrauma) and low-volume injury zone (collapse, atelectotrauma). Animal studies
showed that even a few overinflations can cause relevant lung injury [68] and high tidal
volumes (volutrauma) are more dangerous than high pressures (barotrauma) [86]. A
volume-controlled ventilation uses a constant flow, resulting in a steadily rising (and po-
tentially very high) pressure until the set volume is administered, and the peak pressure is
only achieved at the very end of the inspiration. Volume-targeted ventilation (VTV) differs
substantially from volume-controlled ventilation and combines control over the pressure
and tidal volume. Software algorithms adapt the applied pressure (to a set maximum peak
pressure) to the exhaled tidal volumes of the last couple of inflations in order to achieve an
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expiratory tidal volume matching the set volume as closely as possible [87]. Targeted tidal
volumes are usually set to 4–6 mL/kg in conventional ventilation [87] and 1 to 2 mL/kg
for HFOV [88].
A meta-analysis of the most recent Cochrane review covered 20 RCTs with 977 infants
in 16 parallel group trials, resulting in a reduction of BPD at 36 weeks (RR 0.68, 95% CI
0.53–0.88, n = 620) and BPD or death (RR 0.73, 95% CI 0.59–0.89, n = 584) [76]. A subgroup-
analysis of extremely low birthweight (ELBW) infants did not show significant results
regarding BPD (RR 0.81, 95% CI 0.59–1.12, n = 202) and combined BPD or death (RR 0.79,
95% CI 0.62–1.01, n = 224) [76]. No adverse outcomes were associated with VTV. In contrast,
the meta-analysis showed the benefits of VTV in a shorter mechanical ventilation, lower
pneumothorax rate, lower rates of intracranial abnormalities and less hypocarbic episodes.
An earlier meta-analysis including 18 RCTs came to a very similar result [89]. Since then, a
small RCT has been published in Chinese that reports improved short-term outcomes with
volume-guarantee ventilation in the weaning phase but no impact on BPD [90].
2.4.3. Permissive Hypercapnia
Reducing the parameters of mechanical ventilation in order to allow arterial pCO2 to
rise above 45 mmHg is considered “permissive hypercapnia”. The idea behind permissive
hypercapnia is, if it is not avoidable, at least to decrease the intensity of mechanical
ventilation and to measure the decreased intensity not by the method used but by its
effect: a decreased elimination of CO2 [91]. However, sudden changes in pCO2 should
be avoided, as it rapidly alters the cerebral blood flow and increases the risk for cerebral
hemorrhage [92]. To gain an adequate magnitude of ventilator adjustment, the protocol
of the “Permissive hypercapnia in extremely low birthweight infants” (PHELBI) trial
suggested a pragmatic approach by changing the settings by the same relative magnitude
as the PaCO2 deviation from the target value (e.g., actual PaCO2 40 mmHg and target
PaCO2 > 50 mmHg = 20% off-target → adjustment: a decreased positive inspiratory
pressure (PIP) by 20%) [93].
A Cochrane review included two RCTs, of which one RCT was very small and the
other RCT achieved only a 4-mmHg difference between treatment arms [79]. There was
no significant difference for death or BPD at 36 weeks PMA, nor for any other relevant
outcome. This review has not been updated since 2001. One subsequent RCT randomized
infants between 23 and 28 weeks to either normocapnia (35–45 mmHg) or hypercapnia
(55–65 mmHg) but was terminated early for failure to achieve the desired CO2 difference
in the treatment arms. There were no significant differences in BPD at 36 weeks PMA or
combined BPD or death but an increase in death or mental impairment in the hypercapnia
group (secondary outcome) [94]. The largest RCT (PHELBI trial) was also terminated early
because of very slow recruitment and a lack of funding for further extension [93]. Three
hundred and fifty-nine infants between 23 and 29 weeks were randomized within the first
day of life. Both arms had pCO2 targets that were rising on day 4 and day 7 by 5 mmHg,
ending in 50–60 mmHg in the low versus 65–75 mmHg in the high pCO2 arm. Therefore,
in fact, both groups targeted the hypercapnic pCO2 levels. Although this study was able
to achieve the preset pCO2 levels between treatment arms, there was no difference in the
primary outcome death or BPD at 36 weeks. However, no adverse effect of hypercapnia on
the neurodevelopmental outcome was reported [95].
2.4.4. Supplemental Oxygen
Exposure to oxygen has been associated with BPD. Infants < 30 weeks randomized
to SpO2 target 95–98% have a higher risk of requiring supplemental oxygen at 36 weeks
than infants randomized to 92–94% (OR 1.40, 95% CI 1.15–1.70) [96]. A meta-analysis of the
subsequent RCTs demonstrated a lower rate of supplemental oxygen in infants randomized
to a SpO2 target of 85–89% as opposed to 91–95% (RR 0.81, 95% CI 0.74–0.90), but this was
counteracted by an increased risk of death and necrotizing enterocolitis (NEC) [97]. More
recently, ventilators have been equipped with pulse oximetry and algorithms to adapt
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the inspired fraction of oxygen to the set SpO2 target. It has been established that these
algorithms are able to increase the time spent within the target range and reduce the time at
hypoxia and hyperoxia [98]. However, it is unclear whether these improvements translate
into a reduction of BPD or other patient-relevant outcomes.
2.4.5. Synchronization
Synchronization, either by higher respiratory rates (60–80/min) as compared to lower
rates (30–40/min) or by different triggered ventilation modes, has advantages on the
incidence of air leaks but has no established effect on BPD at 36 weeks [72]. The same
applies for a meta-analysis of RCTs comparing long with short inspiratory times—there
was an advantage for a short inspiration time and higher frequency in terms of air leaks
but not in terms of BPD [78]. A Cochrane review [80] identified one RCT on NAVA versus
pressure-controlled ventilation, which found no difference in the rates of BPD or other
relevant outcomes [99].
2.4.6. Early Extubation
If intubation and mechanical ventilation was either necessary as a life-saving proce-
dure or deemed the least harmful strategy of respiratory support in a particular situation,
it does not mean that it needs to be continued until successful extubation can be safely
predicted. Preterm infants probably benefit from early extubation [100], even if no pre-
extubation test can predict if reintubation will be necessary or not [101–103]. Extubation to
noninvasive ventilation and caffeine will increase the chances of success, while corticos-
teroids should be used judiciously [104].
2.4.7. Tracheostomy Placement
Ongoing intensive respiratory support, e.g., mechanical ventilation or high-level
noninvasive respiratory support, in infants with established severe BPD at around term-
equivalent age prompts the question for further respiratory management. Retrospective
cross-sectional studies have shown an increased placement of tracheostomy in very preterm
infants in US hospitals over the last decades [105,106], while data from the Neonatal
Research Network of Japan have shown a steady rate of interventions [107]. The evidence
on tracheostomy is based on retrospective cohorts or case-control studies only. DeMauro
et al. evaluated the outcome of infants born before 30 weeks of gestation surviving to a PMA
of 36 weeks (n = 8683) [108]. Those with tracheostomy (n = 304) compared to those without
had a higher risk for the composite outcome of death or neurodevelopmental impairment
(adjusted OR 3.3, 95% CI 2.4–4.6) but with a lower mortality rate (OR 0.4, 95% CI 0.3–0.7).
The authors of the study interpreted the results more likely to be a noncausal association of
tracheostomy and neurodevelopmental impairment in these infants [108]. The study also
analyzed the impact of timing of tracheostomy on the composite outcome, favoring earlier
tracheostomy before 120 days of life in contrast to later tracheostomy (OR 0.5, 95% CI
0.3–0.9). A small single center study included 72 infants born before 32 weeks of gestation
or birth weight < 1500 g receiving tracheostomy due to severe BPD (median 51.8 weeks
PMA, median 183 days of life) analyzing the growth parameters and participation in
developmental therapy four weeks before tracheostomy placement and a four-week period
after [109]. Infants showed a significantly higher weekly gain of weight, length and
head circumference after tracheostomy despite a lower caloric intake. Additionally, after
tracheostomy placement, infants had a lower daily sedation requirement and participated
more often in developmental therapies, with a shift of focus from activities promoting
physiologic stability to activities promoting developmental skill acquisition [109].
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Longitudinal studies on the five-year survival rates and decannulation rates of infants
with tracheostomy due to ventilator-dependent BPD show a post-discharge survival of
73–81% and a five-year decannulation rate ranging between 0% to 97%, depending espe-
cially on neurological comorbidities [110–112]. The median age at decannulation was 32 to
38 months in the cited studies [110–112].
2.5. Postnatal Corticosteroids
Inflammation, e.g., due to ventilator-induced lung injury, oxygen toxicity or infection,
contributes mainly to the development of BPD; therefore, the use of corticosteroids (CS)
with a potent anti-inflammatory effect is deemed reasonable. The very widespread use
during the 1980s resulted in increasing rates of adverse neurodevelopmental outcome
(NDO), especially cerebral palsy. That resulted in an almost complete cessation of postnatal
corticosteroid treatment. A (meanwhile updated) meta-regression of Doyle et al. showed
the necessity of risk–benefit assessment, as infants with very high risk might profit from
CS treatment, even regarding the NDO [113]. Two Cochrane reviews exist that evaluated
early (≤seven days) and late (>seven days) CS for the prevention of BPD with a moderate-
to-high quality of evidence that both resulted in a reduction of BPD and BPD or death
and prevented extubation failure. The relevant side effects included an elevated risk
for intestinal perforation, gastrointestinal bleeding, risk of infections, hyperglycemia,
hypertension and hypertrophic cardiomyopathy; therefore, the authors concluded that the
benefits may not outweigh the adverse effects [114,115]. To reduce BPD, the most efficient
CS is dexamethasone, especially in a high-dose regimen (OR 0.29, 95% confidence interval
0.14–0.52, n = 659) analyzed by a network meta-analysis but also has the highest risk for
cerebral paresis (OR 2.02, 95% confidence interval 0.60–4.67, n = 307) [116]. Hydrocortisone
might have fewer side effects, especially regarding NDO. A recent individual patient
data meta-analysis examined the use of low-dose hydrocortisone as a prophylaxis for
early adrenal insufficiency for 10 to 15 days. Treated infants had a higher rate of survival
without BPD (OR 1.45, 95% CI, 1.11–1.90, n = 979) and a reduction of BPD (OR 0.73,
95% CI 0.54–0.98, n = 802) without a difference in death or impaired NDO [117]. However,
the latest SToP-BPD RCT randomized 372 infants in a 22-day course of hydrocortisone
or placebo and failed to show an effect on the BPD or death at 36 weeks PMA [118], and
long-term data are not yet available.
To avoid systemic side effects, topic treatment with CS intratracheal instillation with
surfactant as the vehicle and inhaled CS have been used. The meta-analysis of two trials of
intratracheal instillation CS show a reduction of BPD (RR 0.19, 95% CI 0.10–0.28, n = 381)
and the combined outcome of BPD or death (RR 0.26, 95% CI 0.16–0.35, n = 381) [119];
yet, data on long-term outcomes are not yet published, and further trials are underway.
A meta-analysis of 16 RCTs showed that the inhalation of CS not only reduced the used
amount of systemic CS but also led to a reduction of BPD (RR = 0.77, 95% CI 0.65–0.91,
n = 1168) and BPD or death (RR 0.86, 95% CI 0.75–0.99, n = 1285) [120]. No significant
change in mortality (RR 0.97, 95% CI 0.42–2.2, n = 1270) could be detected. This is of
importance, as the mortality rate of the major contributing NEurOSIS study (n = 863) was
(nonsignificant, but nonetheless) elevated (1.24; 95% CI, 0.91–1.69) [121]. A long-term
follow-up of this study showed no difference in NDO but still an increased mortality rate in
the budesonide group (RR 1.37, 95% CI, 1.01–1.86) [122]. The authors of NEurOSIS did not
find a plausible explanation for the elevated mortality. A meta-analysis of Zheng et al. on
long-term effects of the intratracheal administration of CS, including five trials (n = 1515),
did not find a significant difference in the mortality (RR 1.13, 95 CI 0.90–1.41, n = 1465) but,
also, neither in the benefits regarding NDO nor adverse effects [123].
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2.6. Inhaled Nitric Oxide (iNO)
For the purpose of this review, only the prophylactic use of iNO to prevent BPD will
be examined.
Endogenous NO is required for alveolar and vascular development [124]. Recent
data suggest that there is a relevant vascular component in the development of BPD [125].
There is an association between disturbed NO signaling in BPD; however, it is controversial
whether this causal for resulting from developing pulmonary damage or both [126].
In 2011, the results of an NIH Consensus Development Conference and of an indi-
vidual patient-data meta-analysis have been published. Both concluded that, despite the
sound and plausible pathophysiologic basis, there was no benefit nor harm from prophylac-
tic treatment of preterm infants with iNO [127,128]. At that time, it remained unanswered if
a particular subgroup of infants might benefit from iNO or if there were treatment-relevant
(timing, dose and duration) variables that might explain the gap between basic research
and clinical trials. Data from 12 RCTs were analyzed and yielded in a RR of 0.96 (95% CI
0.92–1.01, n = 3298) for the primary combined outcome of death (RR 1.05, 95% CI 0.93–1.18)
or BPD at 36 weeks PMA (RR 0.93, 95% CI 0.87–1.00). Subgroup analyses indicated a
possible benefit for black infants and for trials with starting dosage >5 ppm [127]. Another
meta-analysis, on which the NIH Consensus Statement was based, found a borderline
significant effect from 14 RCTs for the combined outcome of death or BPD (RR 0.93, 95% CI
0.86–0.99, n = 3129) [129,130].
The most recent Cochrane Review included data from 17 RCTs, including three new
RCTs since 2011 [131]. Due to significant heterogeneity in the inclusion criteria, they
did not perform an overall analysis but divided the trials into three groups: eight trials
of early rescue treatment based on oxygenation, four trials examining early routine use
of iNO in infants with pulmonary disease and three trials with later start of treatment
(>3 days) based on risk of BPD. Risk of death or BPD was similar in all three group of
trials (early rescue: RR 0.94, 95% CI 0.87–1.01, n = 958; early prophylactic: RR 0.94, 95%
CI 0.87–1.02, n = 1924 and late: RR 0.92, 95% CI 0.85–1.01, n = 1075). A nonsignificant
increase of severe intraventricular hemorrhage was found only in the early rescue group
(RR 1.20, 95% CI 0.98–1.47, n = 773), potentially reflecting a side effect due to the inhibition
of platelet aggregation by iNO. One additional RCT, including 451 infants born < 30 weeks
of gestation, has been published. There was no difference in survival without BPD at
36 weeks (OR 1.17, 95% CI 0.79–1.73) or BPD severity or IVH [132].
To answer the question whether iNO might be beneficial for infants of African Ameri-
can descent treated with doses >5 ppm and for >seven days, an individual patient data
meta-analysis from three RCTs was carried out [133]. It demonstrated a reduced risk for
death or BPD (RR 0.77, 95% CI 0.65–0.91) and for BPD alone (RR 0.75, 95% CI 0.61–0.91), no
effect at all for White, non-Hispanic and an intermediate nonsignificant effect for Hispanic
infants [133].
2.7. Inhaled Bronchodilators
Inhaled bronchodilators include nonspecific beta-adrenergic agents, such as isopro-
terenol, and specific beta-adrenergic agents, such as albuterol, metaproterenol, terbutaline
and isoetharine or inhaled anticholinergic agents as atropine or ipratropium. The use of
bronchodilators in BPD has been justified by their potential effect of dilating small airways
that have muscular hypertrophy. Furthermore, BPD is associated with an increased airway
resistance, decreased dynamic compliance and wheezing. If bronchodilators were admin-
istered in short-term studies of pulmonary mechanics in infants with BPD, an increased
compliance, as well as decreased pulmonary resistance, have been documented [134–136].
However, data on clinically relevant outcomes are sparse.
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The most recently updated systematic review from the Cochrane Collaboration in-
cluded only two small studies that reported on 225 infants [137]. One study included
73 infants but reported on 52 infants and examined the prevention of BPD with the use of
aminophylline [138]. Methodological quality was reported to be very low according to the
GRADE classification system. The use of prophylactic aminophylline was associated with
a reduction in BPD at 28 days of life (RR 0.18, 95% CI 0.04–0.74) and a shorter duration
of supplementary oxygen therapy. There was no difference in mortality (RR 3.0, 95% CI
0.33–26.99). The second study included in the Cochrane review enrolled 173 infants to
look at the prevention of BPD with the use of salbutamol [139]. According to GRADE, the
quality of the evidence was moderate. Infants treated with inhaled prophylactic salbutamol
compared to controls showed no differences in mortality (RR 1.08, 95% CI 0.50–2.31) nor
in BPD (RR 1.03, 95% CI 0.78–1.37) or other complications associated with preterm birth.
The study did not report on side effects due to salbutamol. The authors of the systematic
review from the Cochrane Collaboration found no eligible trial that studied the use of
bronchodilator therapy for the treatment of individuals with BPD [137]. Another systematic
review used less strict inclusion criteria and included five further small RCTs (n = 84) on
beta-agonists [140]. However, due to substantial heterogeneity, no meta-analysis could be
performed, and the included studies did only report on short-term measurements with
improvement of compliance and resistance but not on clinically relevant outcomes such
as BPD or mortality [140]. Despite missing evidence, a recent retrospective multicenter
cohort study including 4986 preterm infants born before 32 weeks of gestation with de-
veloping BPD at 28 days of life showed the widespread use of inhaled bronchodilators in
US hospitals [141]. Twenty-five percent (1224/4986) received at least one dose of inhaled
bronchodilators between 28 days of life and discharge or death and, those developing
severe BPD at 36 weeks PMA, even 48% (664/1390).
2.8. Macrolides
Ureaplasma spp. are amongst the most common microbes isolated from maternal
samples, as well as neonatal tracheal aspirates [142], and they might cause a chronic
pulmonary inflammation contributing to the development of BPD [143–145]—in particular,
in ventilated infants [146]. A meta-analysis quantified the OR for BPD at 36 weeks to 2.22
(95% CI 1.42–3.47) for Ureaplasma-positive infants [147]. Macrolides have a role in pediatric
chronic inflammatory pulmonary conditions like cystic fibrosis, so they also might work to
prevent BPD, either by an intrinsic anti-inflammatory effect or by affecting colonization
status with pathogenic bacteria [148].
Erythromycin was evaluated by two small RCTs, which are summarized but not
combined in a meta-analysis in the relevant Cochrane review [149]. Both were randomized
infants < 30 weeks, one with unknown and one with positive colonization status. Neither
showed a significant difference between Erythromycin and no therapy with regard to
death, BPD or the combined. A later meta-analysis evaluated all RCTs on Erythromycin,
Clarithromycin and Azithromycin [150]. They found a borderline nonsignificant effect
of prophylactic macrolides on the combined death or BPD at 36 weeks (RR 0.89, 95% CI
0.79–1.01, n = 438) and a stronger but wider effect in Ureaplasma-positive infants only
(RR 0.41, 95% CI 0.05–3.13, n = 150), with only two studies having a satisfying quality. A
subgroup analysis on prophylactic Azithromycin only could show a reduction of BPD (RR
0.83, 95% CI 0.71–0.97, n = 310) and combined outcome of BPD or death (RR 0.86, 95%
CI 0.77–0.97, n = 363) [150]. However, the most recent meta-analysis for Azithromycin
including five RCTs with 564 moderate to extremely preterm infants found no difference
in BPD, mortality or the combined outcome BPD or death despite the lower duration of
supplemental oxygen [151].
The protocol of the AZTEC trial was published recently [152]; it will randomize 796
infants < 30 weeks to a 10-day course of azithromycin. The trial will also investigate the
incidence of NEC and of resistance to Azithromycin in stool samples, but it will not be
powered to detect the impact of shifts in the microbiome and antimicrobial patterns.
Children 2021, 8, 298 11 of 31
2.9. Microbiome and Antibiotic Treatment
The complex interaction of microbiome of intestines and lungs with the developing
immune system and organ development will likely provide further insight in the devel-
opment of BPD [153]. Microbial dysbiosis may be associated with BPD progression and
severity [145]. A prolonged antibiotic treatment in infants without culture-positive sepsis
and negative inflammatory parameters might lead to such microbial dysbiosis. Higher
rates of antibiotic use in culture-negative sepsis were associated with adverse neonatal
outcomes, including the development of BPD [154]. However, the risk/benefit ratio of
antibiotic use regarding the higher incidence of early- and late-onset sepsis in VLBW and
ELBW infants remains challenging; therefore, the implementation of antibiotic stewardship
to avoid unnecessary antibiotic treatment is recommended [155].
2.10. Patent Ductus Arteriosus
A patent ductus arteriosus (PDA) is a very common morbidity in preterm infants.
In extremely preterm infants ≤ 28 weeks of gestation, an incidence of hemodynamically
significant PDA of 57% has been reported after the first week with an inverse correlation to
gestational age, reaching a maximum of 93% in infants of 23–24 weeks of gestation [156].
The effect of an existing PDA on mortality and morbidities and the resulting urge to treat a
PDA are still a matter of debate [157,158]. A meta-analysis of observational studies found
major morbidities as intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC)
and BPD related with PDA [159]. These results have to be interpreted with caution, as
this association is not necessarily a causality. A meta-analysis of placebo-controlled RCTs
could not show any difference in mortality, IVH, NEC or BPD [160]. However, with a
median 52% rate of rescue treatment in the control groups, the investigators of the meta-
analysis questioned the evidence for good reason [160]. Most RCTs aim at the efficacy to
close the PDA and may be underpowered to estimate the impact on neonatal mortality
or major morbidities [158]. Therefore, all Cochrane meta-analyses on the different phar-
macological treatment options (indomethacin, ibuprofen or paracetamol (acetaminophen)
targeting cyclooxygenase-I) failed to show an effect on mortality or BPD despite being
effective in PDA closure [161–165]. A recent network meta-analysis evaluated RCTs regard-
ing the different pharmacological interventions (indomethacin, ibuprofen, paracetamol
(acetaminophen) or placebo) and found no difference in mortality or morbidities even com-
pared to the placebo but higher rates of side effects as oliguria, especially in indomethacin
and ibuprofen [166]. The same conclusion was drawn in another network meta-analysis on
RCTs and observational studies [167].
The rates of surgical ligation of the PDA decreased substantially in a US cohort of
61,520 preterm infants born between 23 and 30 weeks of gestation from 8.4% in 2006 to
2.9% in 2015 [168]. A meta-analysis of one RCT and 39 cohort studies evaluating surgical
ligation showed a reduced mortality (pooled adjusted OR (aOR) 0.54, 95% CI 0.38–0.77,
n = 7159), but an increase in morbidities such as BPD (pooled aOR 2.51, 95% CI 1.98–3.18,
n = 6703) and higher rates of impaired neurodevelopmental outcome (aOR 1.54, 95%
CI 1.01–2.33) [169]. The potential survival bias was addressed in a retrospective cohort
study including 754 infants adjusting not only for pre- and perinatal confounding factors
but, also, for postnatal factors representing the severity of illness [170]. There was still
a reduction in mortality (aOR 0.09, 95% CI 0.04–0.21) but no more difference in BPD or
the neurodevelopmental outcome [170]. Despite these results, the substantial rates of
procedural complications up 44%, including post-ligation cardiac syndrome, vocal cord
paralysis and acute kidney injury, have to be taken into account [157].
Percutaneous catheter intervention to close the PDA is associated with high rates of
adverse events (23%) and clinically significant adverse events (10%) in a meta-analysis of
observational studies on infants of < one year [171]. A newer device has been approved
for interventional closure of the PDA in preterm infants ≥ 700 g with promising first
results [172], but further studies are necessary before a routine use can be recommended.
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During the last decade, the clinical management of PDA shifted significantly from an
active treatment towards “watchful waiting”, as most PDAs close spontaneously, and all in-
terventions, pharmacological and surgical, have potential adverse effects [156,157,167,173].
A recent Cochrane meta-analysis (14 trials, n = 910 infants) found no difference in mortality
or BPD comparing early treatment before 7 days of life versus expectant management or
very early treatment before 72 h of life and versus expectant management [174].
Watchful waiting should not be interpreted as doing nothing: During “waiting”,
increased positive airway pressure should be applied, and volume overload due to liberal
fluid management should be avoided [175,176] (see section Fluid Management). “Watchful”
means regular clinical and echocardiographic reevaluation of the PDA as recent RCTs
suggest that not a binary variable “PDA existent or not” but the magnitude of PDA shunt
affects the outcome [177]. Exposure to a moderate to large PDA of seven to 13 days led
to an increase of the combined outcome of BPD or death (OR 2.12, 95% CI 1.04–4.32). An
exposure of ≥ 14 days further increased the risk of BPD or death (OR 3.86, 95% CI 2.15–6.96)
and BPD alone (OR 4.09, 95% CI 2.32–7.22) [177].
2.11. Fluid Management and Nutrition
The definition of restrictive or liberal fluid intake varies widely. Sung et al. proposed a
very restrictive approach with 60 mL/kg on the first day of life to <116 mL/kg/day during
the first weeks [175]. Other studies defined low intake as <96 mL/kg on the first day of
life proceeding to <135 mL/kg/d after the first week [178]. The latter is comparable to the
studies included in the Cochrane review of Bell and Acarregui [179] but exceeded that by
Letshwiti et al. (mild fluid restriction 130–150 mL/kg/d) [176] or the applied cut-off value
of <150 mL/kg/d in the Cochrane review of Barrington et al. [180].
The meta-analysis of early fluid management showed a reduction of hemodynamically
significant PDA and NEC with a restrictive water intake, but the impact on BPD (RR
0.85, 95% CI 0.63–1.14) or mortality (RR 0.81, 95% CI 0.54–1.23) was not significant [179].
Comparable results were presented by a cohort study with an increased risk for PDA with
higher fluid intake, but the association with BPD in univariate analysis remained no longer
significant in regression analysis [178]. However, a retrospective secondary analysis of a
RCT cohort could show the association of BPD or death with a high fluid intake and lower
weight loss during the first 10 days of life [181] similar to other cohort studies [182–184].
Evidence on a restrictive fluid management to treat BPD is even scarcer. A Cochrane
meta-analysis found insufficient data on that subject [180], with the only included study not
reporting on mortality or BPD at 36 weeks PMA. The idea of reducing pulmonary edema
with a resulting improvement of pulmonary function and gas exchange due to shorter
diffusion distance is the rational for the widespread use of diuretics in neonatology [180,
185,186]. Meta-analyses of RCTs evaluating loop diuretics as furosemide or diuretics acting
on the distal tubule (thiazide and spironolactone) showed improvement in pulmonary
mechanics but did not report on BPD [187–189]. Only two included small trials on chronic
administration of thiazide-spironolactone showed a decreased mortality rate (RR 0.30, 95%
CI 0.09–0.93; n = 77) [189]. A recent cohort study analyzed the mortality rates of infants with
moderate to severe BPD in 43 US children’s hospitals. There was no difference in mortality
comparing hospitals with “low” and “high” cumulative loop diuretic use [186]. Greenberg
et al. examined a large cohort including 37,693 infants born before 29 weeks of gestation
comparing exposure to furosemide to no exposure in regards of BPD and combined BPD
or death [190]. The binary variable “exposure” yes or no was not significant, but the
percentage of exposure days between the seventh day of life to 36 weeks PMA showed
a reduction of BPD and of BPD or death. They could show an increase in furosemide
exposure days of 10 percentage points, leading to 4.6-percentage point decrease in BPD
(p = 0.001) and a 3.7-percentage point decrease in BPD or death (p = 0.01) [190]. On the
other hand, a prolonged diuretic treatment with furosemide is associated with relevant
side effects as electrolyte imbalances, nephrocalcinosis and ototoxicity [191].
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As energy expenditure is higher in infants with BPD due to a higher respiratory
rate and breathing work [192] and the association of postnatal growth failure with BPD
development [193], early calorie intake likely has an important effect on BPD development.
As a meta-analysis could not find any RCT evaluating standard versus high-energy in-
take [194], evidence for the association of BPD and lower calorie intake is based on cohort
studies [184,193,195]. Especially delayed or prolonged time to full enteral feeding was
associated with BPD development [183,184,193,195,196], but this may be a confounding
factor, as immaturity or more critical condition led to feeding intolerance. A calorie/protein
ratio below that recommended for growth was found in preterm newborns who developed
BPD, and providing nutrition for these newborns remains a challenge [195]
Human milk is known to be protective against NEC [197] and seems to have a protec-
tive effect on BPD development as well. Recent meta-analyses of RCTs and observational
studies found a reduction of BPD in infants fed with human milk compared to preterm
formula (RR 0.78, 95% CI 0.67–0.90) [198,199]. This effect was no longer significant when
only RCTs were evaluated. Another meta-analysis focused on maternal breast milk and
showed a reduction of BPD in exclusively maternal breast milk-fed infants (RR 0.74, 95% CI
0.57–0.96), but as other feeding dosages with maternal breast milk showed no effect, the in-
vestigators suggested caution with the interpretation of the results [200]. Still, human milk
provides various protective mechanisms, including specific nutrients and factors. However,
the protein concentration may vary widely in human milk, and the fortification of human
milk to prevent extrauterine growth failure is essential [201]. Standardized fortification
with a fixed amount of fortifier per 100 mL of human milk is still the most applied method
in NICUs. Individualized fortification, which is adjustable fortification (by measuring the
infant’s blood urea nitrogen) or targeted fortification (measuring the macronutrient content
of human milk), seems to be superior compared to standardized fortification regarding
the gain of growth parameters in a recent Cochrane meta-analysis, but the included seven
studies did not present data on the development of BPD or long-term outcomes [202].
Last, human milk has an important influence on the immature microbiome, which is an
important focus of very recent research [153].
2.12. Vitamin A
Vitamin A supplementation is one of the prevention strategies that has stood the test
of time [203] from old to new BPD, from the first RCT in 1987 [204] until the latest meta-
analysis in 2021 [205]. During the fetal period, vitamin A is crucial for respiratory epithelial
cells, cellular differentiation and surfactant production and vitamin A levels were found
to be lower in subjects developing BPD [206], prompting the idea, that supplementation
might reduce incidence or severity of BPD.
A Cochrane review showed a small risk reduction of death or oxygen requirement
at 28 days of life (RR 0.93, 95% CI 0.88–0.99) and of BPD at 36 weeks PMA (RR 0.87, 95%
CI 0.77–0.99, n = 986). However, including mortality as a combined outcome at 36 weeks
PMA yields in loss of significance (RR 0.92, 95% CI 0.84–1.01) [207]. A meta-analysis on
infants with a birth weight < 1000 g (ELBW) only found a decrease in BPD at 36 weeks
PMA (RR 0.88, 95% CI 0.77–0.99, n = 1011) without an effect on mortality or oxygen use at
28 days of life [208], comparable to a more recent but smaller meta-analysis of only two
RCTs [209]. Ding et al. showed in the most recent meta-analysis a reduced incidence of
BPD at 36 weeks PMA (OR 0.67, 95% CI 0.52–0.88) without a difference in mortality or other
morbidities [205]. However, the effect might not be big enough to justify repeated painful
intramuscular injections, and it has also been questioned, whether under the circumstances
of current neonatal intensive care standard therapies, the supplementation with vitamin A
is still essential [210]. Two very recent RCTs analyzed enterally administered vitamin A at
5000 IU per day [211] or 10,000 IU every other day [212] and found higher plasma retinol
levels in the same range of previous non-enteral studies [213]. Despite that, the Australian
study found no difference in BPD or mortality in the 188 included infants born <28 weeks
of gestation likely to the low baseline incidence of BPD in their cohort [211]. The Indian
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study of Basu et al. examined 196 VLBW infants and found a reduction of the composite
outcome death or oxygen requirement at 28 days of life (RR 0.44, 95% CI 0.23–0.84) and
a nonsignificant reduction of BPD at 36 weeks PMA (RR 0.22, 95% CI 0.05–1.00) [212]. A
lower dose of oral vitamin A of 1500 IU per day was administered to infants born <28 weeks
of gestation in a RCT for the prevention of retinopathy of prematurity (ROP) and resulted
in a reduction of BPD (RR 0.56, 95% CI 0.37–0.86, n = 262) [214]. Two further trials are
waiting for completion [215] or full publication [216]; it is to be expected that, in particular,
the NeoVitaA-Trial [217] will add substantial information to the question whether there is
a place for high-dose vitamin A under the circumstances of current high-standard neonatal
intensive care.
2.13. BPD Associated Late Pulmonary Hypertension
A dysregulated angiogenesis during BPD development results in smaller pulmonary
arteries and reduced capillary density. This can lead to increased pulmonary vascular
resistance, followed by remodeling of the pulmonary arteries [218]. Therefore, infants with
BPD are at high risk to develop pulmonary hypertension (PH). A recent meta-analysis
calculated an overall prevalence of PH of 20% in preterm infants, with a distribution of
2% in the absence of BPD, 6% for mild BPD, 12% for moderate BPD and 39% for severe
BPD [219], comparable to the results of an earlier meta-analysis [220]. Both studies reported
on an around five-fold higher mortality of infants with BPD and PH compared to BPD
alone. Furthermore, PH was associated with more frequent readmissions and a high post-
discharge mortality [221–223]. In surviving infants, BPD-associated PH resolved in the
majority of cases during the first two years of life [222,223]. PH is not uniformly defined
in neonates and is usually estimated via echocardiography. Right ventricular systolic
pressures (RVSP) > 40 mmHg measured via tricuspid regurgitation jet velocity (plus an
estimated 5 mmHg of right atrial pressure), a RVSP/systemic systolic blood pressure ratio
> 0.5, a systolic flattening of the interventricular septum or right-to-left or bidirectional
cardiac shunt or PDA are the most common noninvasively obtained parameters [223,224].
The management of BPD therefore has to include an echocardiographic screening for PH,
as suggested by the consensus guidelines of the European Pediatric Pulmonary Vascular
Disease Network (EPPVDN) [225,226]. At least at diagnosis of BPD with 36 weeks PMA, an
echocardiography should be performed to assess a possible PH [225–227]; other algorithms
recommend serial examinations from the seventh day of life for an earlier diagnosis of
PH [218]. Infants with signs of PH in a predischarge echocardiography should be referred
to an outpatient cardiologic follow-up [227].
Treatment options include oxygen therapy, diuretics and pulmonary vasodilators [225].
The question of the “right” targeted SpO2 level in neonatal care has been the objective of
many studies. A recent retrospective cohort study found a reduced incidence of PH with
a higher targeted SpO2 of 90–95% [228]. The recommendation of EPPVDN even exceeds
this threshold in infants with established PH, suggesting an oxygen saturation ≥ 93% in
suspected and even ≥ 95% in proven PH [225]. At least there is robust evidence to avoid
pulmonary vasoconstriction due to prolonged hypoxic episodes of SpO2 ≤ 85% but, also,
the effect of oxygen toxicity due to hyperoxic episodes >97% [225,229].
A recent retrospective cohort study analyzed the effect of a first-line diuretic therapy
in infants with BPD associated PH with substantial improvement in respiratory symptoms
within one week in 90% of treated infants but without a difference in mortality or NDO [227].
It has to be mentioned that all infants in this cohort received a high total fluid intake of 155 to
158 mL/kg/d. As mentioned in Section Fluid Management, a more restrictive fluid regimen
should be considered before diuretic therapy or at least after the start of diuretic therapy
(thiazide plus spironolactone), as suggested by EPPVDN, as long as the cardiac preload is
adequate [225]. In the case of disease progression, pulmonary vasodilator therapy should
be considered after ruling out a pulmonary vein stenosis, which is often associated with
premature birth [223,225–227,230]. Phosphodiesterase-5 inhibitors as sildenafil have been
examined in retrospective cohorts, but there has been no evidence from RCTs or prospective
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studies exists regarding BPD-associated PH treatment with sildenafil so far. Results of
a meta-analysis show an improvement in respiratory scores in 15% within two–seven
days and an improvement in 69% patients regarding echocardiographic parameters of PH
within one to six months without reports on serious side effects [231]. This is important, as
the Food and Drug Administration (FDA) in 2012 gave an official warning on the use of
sildenafil in children, especially when using higher doses [232]. However, an additional
systematic review including RCTs and observational studies found the low-to-moderate
dose administration of sildenafil in (older) children with pulmonary hypertension due to
various causes efficient and safe [233]. With the results of both meta-analyses and following
the recommendation of the EPPVDN consensus statement, the use of sildenafil (initial
dose of 1 mg/kg/d titrated to a maximum dosage of 4 (to 6–8) mg/kg/d) in infants with
progressive PH associated to BPD can be considered [218,225,226].
2.14. Stem Cell Therapy for BPD—An Outlook to a Present Future
During the last decade, stem cell therapy for the prevention and therapy of neonatal
diseases has become a major research focus, with very promising results in preclinical
studies [234]. Mesenchymal stem cells (MSC) are the best examined stem cell type and
have shown the most potent effect on prevention or treatment of BPD in a network meta-
analysis of the preclinical studies [235]. MSC are multipotent stem cells, which can be
extracted from bone marrow or adipose tissue or, much easier, with a higher proliferative
activity and the potential of autologous therapy from the amniotic hulls, umbilical cord
or umbilical cord blood [234,236]. The regenerative mechanism is, in contrast to the first
speculations, not by cell replacement (engraftment < 1–5%) but seems to depend mostly
on paracrine mechanisms [234,236]. These consist of bioactive substances as signaling
peptides and growths factors, extracellular matrix proteins and exosomes. The latter are
membrane-bound vesicles transferring proteins and microRNA into targeted surrounding
cells acting with transcriptional and posttranslational modifications in these cells [234]. This
explains the evident improvement of alveolarization, angiogenesis and pulmonary arterial
remodeling by cell-free therapy with MSC-conditioned media in another meta-analysis of
preclinical studies [237]. One very recent study reported on the effect of MSC-conditioned
media on structural and functional lung maturation, therefore targeting the lung tissue
immaturity itself [238]. The network-meta-analysis still found MSC therapy superior to
MSC-conditioned media regarding all four analyzed clinically relevant outcomes (alveo-
larization, lung angiogenesis, pulmonary hypertension and lung inflammation) [235]. All
studies evaluating the safety of MSC-based therapy found no short- or long-term adverse
effects, but the results have to be interpreted with caution, as almost exclusively rodent
models were used in the included studies [235]. Nonetheless, in 2014, the results of the
first human MSC phase I trial administering 107 or 2 × 107 human cord blood-derived
MSCs intratracheally to nine preterm infants at high risk for BPD were published [239].
MSC therapy was well-tolerated, and a reduction in inflammatory parameters in tracheal
aspirates could be shown, as well as a reduction of BPD severity compared to a historical
cohort [239]. One infant died due to sepsis at the age of six months, but the two-year
follow-up of this phase I trial showed no signs of transplantation-related adverse events,
including tumor formation [240]. At the moment of writing the draft of this manuscript (5
February 2021), twelve recruiting or completed phase I and phase II studies evaluating the
prevention or therapy of BPD with stem cells or stem cell-conditioned media have been
registered at ClinicalTrials.gov, plus an additional four follow-up studies.
Children 2021, 8, 298 16 of 31
3. Recommendations for the Everyday BPD Management Based on the
Presented Evidence
In the following paragraphs, we present evidence-based recommendations for BPD
management in very preterm infants. Additionally, Table 2 summarize the recommenda-
tions for BPD prevention, while Table 3 includes the recommendations for BPD therapy.
3.1. Antenatal Corticosteroids
ANS is an effective method in the reduction of mortality and the combined outcome of
BPD or death in very preterm infants. Timing of ANS is an issue, as ANS is most effective
in an interval of >24 h to seven days after the last injection. As the outcome is significantly
better with an ANS course longer than seven days compared to none, ANS should be
administrated in case of impending preterm birth before 34 weeks of gestation. A rescue
retreatment should be considered if the first course has been completed more than one
week before.
3.2. Surfactant-Replacement Therapy
Surfactant-replacement therapy is an essential therapy in neonatology and improved
survival rates of much more immature preterm infants. Animal derived surfactant seems
to be superior to synthetic surfactant, and there is weak evidence that poractant is superior
to bovine surfactant. More important is the way of surfactant administration, especially in
regard to the recommended noninvasive respiratory support: recent meta-analyses consis-
tently show the superiority of LISA/MIST compared to invasive surfactant administration
regarding mortality, combined BPD or death and BPD development. Therefore, this should
be the preferred way of surfactant administration if the expertise of the attending physician
regarding this technique is sufficient.
3.3. Caffeine
Based on the currently available high-level evidence from RCTs, mainly CAP, treat-
ment with caffeine with the intention to reduce the risk of BPD can be recommended.
This recommendation focuses on extremely preterm infants, since this patient group was
enrolled in CAP and is also the patient group with the highest risk of developing BPD. To
start caffeine treatment in the first three days of life may be considered, especially in those
infants that already receive noninvasive ventilatory support, since early caffeine may help
to avoid invasive ventilation in these infants.
3.4. Ventilation Strategies
If possible by the use of noninvasive respiratory support, mechanical ventilation
should be avoided. Unfortunately, neither an optimal PEEP level for a group of infants
based on pathology or patient characteristics, nor a strategy to identify the optimal level for
an individual infant, could be established so far [77]. Whenever mechanical ventilation was
inevitable, lung-protective ventilation strategies should be applied, and the goal should be
the earliest reasonable extubation.
3.4.1. High-Frequency Oscillation Ventilation
As modern respirators have evolved in terms of synchronization and tidal volume
measurements, a comparison between volume-targeted ventilation modes and HFOV
might be more relevant to neonatologists in the 2020s [84]. In the absence of valid recent
data and with relatively small differences from meta-analyses of RCTs performed in the
last four decades, it is difficult to make clear recommendations.
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3.4.2. Volume-Targeted-Ventilation (VTV)
Although the evidence for the most vulnerable group of ELBW infants is not as strong
as for all newborn infants together, we believe it is strong enough to use VTV as the
preferred mode of conventional ventilation, whenever it is possible.
3.4.3. Permissive Hypercapnia
Although not supported by clear evidence, permissive hypercapnia is widely used in
European NICUs [241]. While the randomized studies demonstrated difficulties in strict
protocol adherence, probably because some infants require different pCO2 targets than
those prescribed by randomization, there is no evidence to support the universal pCO2
target of 45 mmHg for every preterm infant. Most likely, there is a threshold beyond which
intensifying the pressure, tidal volume or amplitude is increasingly harmful, and it might
be wiser to let pCO2 increase a bit higher instead of pushing ventilator settings further and
further—but we still do not know where this threshold is and if it is the same for every
infant.
3.4.4. Supplemental Oxygen
Oxygen therapy in very preterm infants remains a balancing act. Oxygen saturation
levels in the low 90s% should be targeted, as lower ranges (85–89%) were associated with
an increased mortality [97]. In infants with suspected or proven pulmonary hypertension,
the inspired fraction of oxygen should aim at higher oxygen saturation levels of 93% and
95%, respectively.
3.5. Tracheostomy Placement
There is insufficient evidence for the criteria and/or optimal timing of tracheostomy.
Infants with persisting ventilator-dependency (mechanical ventilation or high-level non-
invasive respiratory support) beyond the neonatal period might profit from a reduced
sedative medication after tracheostomy and the possibility of more parent–child interaction
and development supporting therapies and environment.
3.6. Postnatal Corticosteroids
CS have a beneficial effect on the development of BPD but are associated with severe
short-term side effects and no clear-cut effect on the neurodevelopmental outcome. There
is evidence that dexamethasone is more efficient than hydrocortisone, while the latter
is potentially associated with lesser impact on NDO. The use of systemic CS, preferably
dexamethasone, should be limited to repeated failure to extubate due to developing BPD.
Increasing evidence exists for the BPD prevention with topic CS administration, yet with
the unclear nonsignificant increase in mortality of NEurOSIS and paucity of long-term data
after intratracheal instillation of CS, at this moment, the routine use of topic CS treatment
cannot be recommended.
3.7. Inhaled Nitric Oxide (iNO)
There is no indication for iNO as a general prophylactic therapy to prevent BPD.
It is unclear, whether there is increased risk for severe intraventricular hemorrhage for
early rescue therapy, so iNO should be restricted for the most severe cases of hypoxemic
respiratory failure. Only for preterm infants of African American descent, high dose
prophylactic therapy should be considered.
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3.8. Inhaled Bronchodilators
There is too little evidence to show positive or negative effects of bronchodilators
for prevention of chronic lung disease, and thus, at the moment, inhaled bronchodilators
should not be used routinely for this indication.
3.9. Macrolides
A beneficial effect of macrolides on BPD—in particular, in ventilated Ureaplasma-
positive infants treated for a longer duration—cannot be ruled out. However, as long as
this is not proven as a primary endpoint in rigorously conducted RCTs of sufficient size,
and as long as safety concerns are not sufficiently addressed, we do not recommend routine
treatment with macrolides.
3.10. Patent Ductus Arteriosus
Beside restrictive fluid intake (Section Fluid Management) and application of contin-
uous positive airway pressure, no uniform recommendation regarding the management
of the PDA can be given, as some particularly vulnerable patients may benefit from early-
targeted treatment, and some infants may even profit from surgical ligation if pharmacolog-
ical treatment fails. Therefore, Hamrick et al. presented a differentiated treatment algorithm
considering demographic factors, echocardiographic findings and clinical assessment [157].
3.11. Fluid-Management and Nutrition
Moderate early restrictive fluid management in infants with hemodynamically signifi-
cant PDA and/or high risk for BPD is recommended with a fluid intake of approximately
60–80 mL/kg on first day stepwise increasing by 10–20 mL/kg to a total of 130 mL/kg/d.
Fluid balance, diuresis and weight loss should be carefully monitored especially during
parenteral fluids are given to the infant.
To avoid unnecessary exposure to diuretics, fluid restriction should be continued in
infants with signs of developing BPD as increasing need for supplemental oxygen or mean
airway pressure. The physician has to weigh benefits against potential harms of a diuretic
therapy. A longer treatment with thiazide plus spironolactone should only be administered
if a beneficial effect on pulmonary mechanics as reduction of supplemental oxygen or mean
airway pressure occurs during probatory treatment (with loop diuretics or diuretics acting
on the distal tubule).
Sufficient energy supply has to be guaranteed even during reduction of water intake.
To address the higher energy consumption in established BPD, a daily energy intake of
>135 kcal/kg is recommended.
Early enteral feeding preferably with maternal breast milk or human donor milk may
reduce development of BPD. Individualized fortification of human milk is superior to
standardized fortification regarding growth parameters but there is insufficient evidence
regarding BPD development.
3.12. Vitamin A
Taking into account the presumably small effect size and the sufficient enteral absorp-
tion, we believe it is not justified our patients to repeated intramuscular injections. Until
the results of NeoVitaA tell us otherwise, we recommend supplementation of vitamin A as
part of the lipid infusion in parenterally fed infants and with a water-soluble preparation
in enterally fed infants in the upper range of current guidelines [242,243].
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Table 2. Preventive strategies for BPD.
Evidence-Based Preventive Strategies for BPD
Antenatal corticosteroids
• Administer ANS if preterm birth < 34 weeks of GA is impending.
• One course of rescue-Treatment, if first course completed > 1 week ago.
Surfactant replacement therapy
• Early surfactant replacement in surfactant-deficient preterm infants.
• LISA/MIST in combination with noninvasive ventilation is superior to surfactant
with ongoing or even short invasive ventilation.
Caffeine • Early administration within the first 72 h, mainly to prevent invasive ventilation.
Ventilation strategies
• Avoid invasive ventilation by the use of noninvasive respiratory support.
• Lung-protective ventilation: volume-targeted ventilation.
• Supplemental oxygen-targeting SpO2 levels in low 90s%, with higher thresholds
only in the case of pulmonary hypertension.
• Aim at early extubation.
Systemic postnatal corticosteroids
• Dexamethasone is more effective than hydrocortisone, but the latter might have a
lesser impact on neurodevelopmental outcome.
• Limit systemic postnatal corticosteroid therapy to facilitate successful extubation
only after repeated extubation failure.
Fluid management and nutrition
• Moderate early restrictive fluid management starting from 60–80 mL/kg/d and
increasing to 130 mL/kg/d. Careful monitoring of diuresis and weight loss is
recommended.
• Human milk, especially own mother’s milk, may prevent BPD development.
• Provide parenteral or enteral vitamin A supplementation in the upper range of
the current guidelines.
Preventive strategies for BPD with unclear evidence
High-frequency oscillation ventilation • Lack of RCTs comparing volume-targeted ventilation and HFOV
Permissive hypercapnia • Unclear (and likely individually different) threshold for the targeted pCO2 level.
Topic corticosteroids
• Inhaled CS effectively prevented BPD but with an unclear (nonsignificant)
increase in mortality in the largest NEurOSIS trial.
Macrolides
• Insufficient evidence for the efficiency and long-term safety for the routine use of
macrolides.
• Treat infants with proven Ureaplasma spp. pneumonia with macrolides.
Patent ductus arteriosus
• Apply fluid restriction and sufficient positive airway pressure to reduce the risk
for relevant PDA. No uniform recommendation can be given for PDA treatment.
• Risk-adapted screening and treatment algorithms have been recently published.
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Table 2. Cont.
Preventive strategies for BPD with a lack of evidence
Inhaled nitric oxide
• No prophylactic therapy of iNO.
• Infants of African-American descent might profit from high-dose prophylactic
therapy.
• iNO should be restricted to severe hypoxemic respiratory failure with
echocardiographic signs of elevated pulmonary vascular resistance.
Inhaled bronchodilators • Lack of evidence for the preventive use of inhaled bronchodilators.
Abbreviations: ANS antenatal corticosteroids, GA gestational age, LISA less invasive surfactant administration, MIST minimally invasive
surfactant therapy, BPD bronchopulmonary dysplasia, RCT randomized controlled trial, HFOV high-frequency oscillation ventilation,
pCO2 partial pressure of carbon dioxide, NEurOSIS “Neonatal European Study of Inhaled Steroids”, iNO inhaled nitric oxide.
3.13. BPD-Associated Pulmonary Hypertension
Echocardiographic screening for BPD-associated PH should be performed at 36 weeks
PMA and, eventually, in pre-discharge infants with a high risk for PH. In these infants,
outpatient cardiologic follow-up is recommended. The treatment of BPD-associated PH
should include higher targeted oxygen saturation and restrictive fluid management. Di-
uretic therapy with thiazide and spironolactone are first-line pharmacological treatments;
in the case of disease progression, low-to-moderate dose sildenafil therapy should be
considered.
3.14. Stem Cell Therapy
Despite the promising results, the administration of MSC or MSC-conditioned media
for the treatment of BPD should be limited to controlled trials until efficacy and, especially,
long-term safety have been proven by sufficiently powered randomized controlled trials.
Table 3. Therapeutic strategies for BPD.
Evidence-Based Therapeutic Strategies for BPD
Fluid management and nutrition
• Continue fluid restriction in infants showing early signs of developing BPD (e.g.,
increasing the oxygen demand or respiratory support) or proven BPD.
• Higher-energy expenditure necessitates a higher caloric intake of > 135
kcal/kg/d by an increased fortification of milk.
Systemic postnatal corticosteroids
• Prevention and therapy cannot be well-distinguished; therefore, the
recommendation is the same as written above.
Therapeutic strategies for BPD with unclear evidence
Diuretic therapy
• Diuretics may improve the pulmonary mechanics. Consider long-term diuretic
therapy with thiazide and spironolactone if a probatory therapy with furosemide
is effective.
• First-line therapy in BPD-associated PH.
Stem cell therapy
• Despite promising results, stem cell therapy should be limited in clinical trials
until sufficient evidence for the long-term safety and effects is presented.
Abbreviations: BPD bronchopulmonary dysplasia, PH pulmonary hypertension.
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4. Conclusions
BPD management remains an extremely challenging task, and the presented strategies
for everyday work in a neonatal intensive care unit should be considered to improve the
survival and outcome of very preterm infants.
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